Atea Pharmaceuticals Net Income
| AVIR Stock | USD 4.03 0.00 0.00% |
As of the 2nd of February, Atea Pharmaceuticals shows the risk adjusted performance of 0.1056, and Mean Deviation of 2.26. Atea Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atea Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Atea Pharmaceuticals is priced correctly, providing market reflects its regular price of 4.03 per share. Given that Atea Pharmaceuticals has jensen alpha of 0.4243, we suggest you to validate Atea Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.
Atea Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 58.974 | Revenue | Earnings Share (1.77) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -151.5 M | -144 M | |
| Net Loss | -104.3 M | -99.1 M | |
| Net Loss | -151.5 M | -144 M | |
| Net Loss | (2.30) | (2.18) | |
| Net Income Per E B T | 0.90 | 0.77 |
Atea | Net Income | Build AI portfolio with Atea Stock |
Evaluating Atea Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Atea Pharmaceuticals's fundamental strength.
Latest Atea Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Atea Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Atea Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Atea Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Atea Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atea Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (168.38 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Atea Net Income Regression Statistics
| Arithmetic Mean | (41,209,334) | |
| Geometric Mean | 24,548,154 | |
| Coefficient Of Variation | (182.83) | |
| Mean Deviation | 59,966,942 | |
| Median | (9,064,000) | |
| Standard Deviation | 75,342,458 | |
| Sample Variance | 5676.5T | |
| Range | 289.6M | |
| R-Value | (0.61) | |
| Mean Square Error | 3803.7T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | (9,097,512) | |
| Total Sum of Squares | 90823.8T |
Atea Net Income History
Other Fundumenentals of Atea Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Atea Pharmaceuticals Net Income component correlations
Atea Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Atea Pharmaceuticals is extremely important. It helps to project a fair market value of Atea Stock properly, considering its historical fundamentals such as Net Income. Since Atea Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atea Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atea Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Pharmaceuticals industry sustain growth momentum? Does Atea have expansion opportunities? Factors like these will boost the valuation of Atea Pharmaceuticals. If investors know Atea will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Atea Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 2.641 | Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 2.952 | Return On Assets |
Atea Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Atea's balance sheet. Smart investors calculate Atea Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Atea Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Atea Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Atea Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Atea Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Atea Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Atea Pharmaceuticals.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Atea Pharmaceuticals on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Atea Pharmaceuticals or generate 0.0% return on investment in Atea Pharmaceuticals over 90 days. Atea Pharmaceuticals is related to or competes with Voyager Therapeutics, Vanda Pharmaceuticals, Allogene Therapeutics, Entrada Therapeutics, Pyxis Oncology, Humacyte, and Enanta Pharmaceuticals. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commerci... More
Atea Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Atea Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Atea Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.6 | |||
| Information Ratio | 0.1219 | |||
| Maximum Drawdown | 17.79 | |||
| Value At Risk | (4.43) | |||
| Potential Upside | 5.54 |
Atea Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atea Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Atea Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Atea Pharmaceuticals historical prices to predict the future Atea Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1056 | |||
| Jensen Alpha | 0.4243 | |||
| Total Risk Alpha | 0.286 | |||
| Sortino Ratio | 0.1156 | |||
| Treynor Ratio | 0.5963 |
Atea Pharmaceuticals February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1056 | |||
| Market Risk Adjusted Performance | 0.6063 | |||
| Mean Deviation | 2.26 | |||
| Semi Deviation | 3.02 | |||
| Downside Deviation | 3.6 | |||
| Coefficient Of Variation | 740.09 | |||
| Standard Deviation | 3.41 | |||
| Variance | 11.63 | |||
| Information Ratio | 0.1219 | |||
| Jensen Alpha | 0.4243 | |||
| Total Risk Alpha | 0.286 | |||
| Sortino Ratio | 0.1156 | |||
| Treynor Ratio | 0.5963 | |||
| Maximum Drawdown | 17.79 | |||
| Value At Risk | (4.43) | |||
| Potential Upside | 5.54 | |||
| Downside Variance | 12.93 | |||
| Semi Variance | 9.13 | |||
| Expected Short fall | (2.46) | |||
| Skewness | 0.1375 | |||
| Kurtosis | 4.94 |
Atea Pharmaceuticals Backtested Returns
Atea Pharmaceuticals appears to be slightly risky, given 3 months investment horizon. Atea Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the company had a 0.15 % return per unit of standard deviation over the last 3 months. By analyzing Atea Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.51% is justified by implied risk. Please makes use of Atea Pharmaceuticals' risk adjusted performance of 0.1056, and Mean Deviation of 2.26 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Atea Pharmaceuticals holds a performance score of 11. The firm shows a Beta (market volatility) of 0.76, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Atea Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Atea Pharmaceuticals is expected to be smaller as well. Please check Atea Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Atea Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.14 |
Insignificant predictability
Atea Pharmaceuticals has insignificant predictability. Overlapping area represents the amount of predictability between Atea Pharmaceuticals time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Atea Pharmaceuticals price movement. The serial correlation of 0.14 indicates that less than 14.0% of current Atea Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.14 | |
| Spearman Rank Test | -0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Atea Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Atea Pharmaceuticals reported net income of (168.38 Million). This is 149.34% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 129.49% higher than that of the company.
Atea Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atea Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics of similar companies.Atea Pharmaceuticals is currently under evaluation in net income category among its peers.
Atea Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Atea Pharmaceuticals from analyzing Atea Pharmaceuticals' financial statements. These drivers represent accounts that assess Atea Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Atea Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 740.4M | 400.4M | 254.3M | 282.3M | 324.6M | 308.4M | |
| Enterprise Value | (23.8M) | (243.2M) | 112.9M | 219.2M | 252.1M | 239.5M |
Atea Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atea Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atea Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Atea Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Atea Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Atea Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atea Pharmaceuticals' value.| Shares | Northern Trust Corp | 2025-06-30 | 675.5 K | Jpmorgan Chase & Co | 2025-06-30 | 652.7 K | Charles Schwab Investment Management Inc | 2025-06-30 | 635.3 K | Newtyn Management Llc | 2025-06-30 | 580 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 544.3 K | Cm Management, Llc | 2025-06-30 | 500 K | Peapod Lane Capital Llc | 2025-06-30 | 452.5 K | Almitas Capital Llc | 445.4 K | Two Sigma Investments Llc | 2025-06-30 | 366.6 K | Blackrock Inc | 2025-06-30 | 8.7 M | Bml Capital Management Llc | 2025-06-30 | 7.6 M |
Atea Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | (22.79 M) | ||||
| Shares Outstanding | 78.13 M | ||||
| Shares Owned By Insiders | 12.91 % | ||||
| Shares Owned By Institutions | 72.66 % | ||||
| Number Of Shares Shorted | 7.3 M | ||||
| Price To Earning | 15.03 X | ||||
| Price To Book | 1.05 X | ||||
| Price To Sales | 1.90 X | ||||
| Gross Profit | (120.09 M) | ||||
| EBITDA | (131.8 M) | ||||
| Net Income | (168.38 M) | ||||
| Cash And Equivalents | 684.48 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 1.64 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 27.46 X | ||||
| Book Value Per Share | 4.04 X | ||||
| Cash Flow From Operations | (135.5 M) | ||||
| Short Ratio | 18.82 X | ||||
| Earnings Per Share | (1.77) X | ||||
| Target Price | 7.67 | ||||
| Number Of Employees | 56 | ||||
| Beta | 0.08 | ||||
| Market Capitalization | 331.26 M | ||||
| Total Asset | 464.67 M | ||||
| Retained Earnings | (364.22 M) | ||||
| Working Capital | 443.75 M | ||||
| Current Asset | 97.88 M | ||||
| Current Liabilities | 6.25 M | ||||
| Net Asset | 464.67 M |
About Atea Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atea Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Atea Stock
| 0.8 | PBCRY | Bank Central Asia | PairCorr |
| 0.67 | JUNS | Jupiter Neurosciences | PairCorr |
| 0.61 | MMM | 3M Company | PairCorr |
| 0.49 | PBCRF | PT Bank Central | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.